News
-
-
PRESS RELEASE
Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugate
Ipsen expands pipeline with Simcere Zaiming's novel antibody drug conjugate SIM0613 targeting LRRC15 protein for enhanced tumor penetration and anti-tumor activity. Phase I expected in H2 2026 -
-
-
-
-
-
PRESS RELEASE
Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance
Ipsen reports strong sales growth in first nine months of 2025, upgrades full-year guidance, and announces acquisition of ImCheck Therapeutics. Financial results and pipeline updates detailed -
-